Table 7. Risk factors for TB recurrence in successfully treated new smear positive pulmonary TB patients [N = 1108].

Characteristics		No. successfully treated N = 1108	TB recurrence				RR [95% CI]	p value	ARR[95% CI]	p value
			Yes N = 158		No N = 950
		N	n	%	N	%
Sex	Male	769	132	17	637	83	2.23[1.47–3.40]	<0.001	2.43[1.29–4.58]	0.006
	Female	339	26	8	313	92	Ref		Ref
Age-group (years)	≥65	90	9	10	81	90	0.75[0.35–1.61]	0.47
	55–64	163	17	10	146	90	0.79[0.43–1.45]	0.45
	45–54	227	34	15	193	85	1.13[0.68–1.88]	0.61
	35–44	190	33	17	157	83	1.31[0.79–2.19]	0.28
	25–34	233	38	16	195	84	1.23[0.75–2.02]	0.39
	18–24	205	27	13	178	87	Ref
Body Mass Index	≥23	88	9	10	79	90	0.99[0.47–2.07]	0.97	0.77[0.26–2.27]	0.64
	16–18.4	360	53	15	307	85	1.42[0.91–2.21]	0.12	0.99[0.59–1.67]	0.99
	< 16	361	65	18	296	82	1.73[1.13–2.66]	0.01	1.22[0.73–2.05]	0.44
	18.5–22.9	299	31	10	268	90	Ref		Ref
Baseline sputum	2+ / 3+	607	94	15	513	85	1.21[0.88–1.66]	0.23
smear grade	Scanty/ 1+	501	64	13	437	87	Ref
Baseline sputum	2+ / 3+	487	77	16	410	84	1.05[0.76–1.46]	0.73
culture grade	Cols/ 1+	468	70	15	398	85	Ref
Baseline drug	Resistant	71	10	14	61	86	0.92[0.48–1.76]	0.81
Susceptibility test	Sensitive	848	129	15	719	85	Ref
Diabetes mellitus and anti-diabetic medications	Diabetic not on anti-diabetic treatment	85	6	7	79	93	0.45[0.20–1.02]	0.06	0.34[0.12–1.12]	0.07
	Diabetic on anti-diabetic treatment	138	14	10	124	90	0.65[0.37–1.12]	0.12	1.02[0.48–2.20]	0.94
	Non-diabetic	885	138	16	747	84	Ref		Ref
HIV status	Reactive, not on ART	2	0	0	2		Indeterminate
	Reactive, on ART	19	4	21	15	79	1.49[0.55–4.01]	0.43
	Non-reactive	1087	154	14	933	86	Ref
Duration of	3 months	128	14	11	114	89	0.73[0.42–1.27]	0.28
Intensive Phase	2 months	973	144	15	829	85	Ref
Type of DOT	Community based	402	57	14	345	86	0.98[0.70–1.35]	0.89
	Health center based	690	100	14	590	86	Ref
Smoking during	Yes	429	78	18	351	82	1.53[1.12–2.10]	0.007	1.13[0.70–1.84]	0.61
treatment and or	No	651	77	12	574	88	Ref		Ref
follow-up
Taking alcohol	Yes	428	76	18	352	82	1.46[1.07–2.00]	0.017	1.06[0.66–1.71]	0.81
during treatment	No	652	79	12	573	88	Ref		Ref
and or follow-up
Respiratory	No	614	101	16	513	84	2.33[0.95–5.7]	0.06	2.43[0.97–6.07]	0.06
symptom at end	Any	71	5	7	66	93	Ref		Ref
of treatment	symptom
Duration of	>28	294	42	14	252	86	1.85[0.25–13.49]	0.54
anti-TB treatment	>24 to 28	796	115	14	681	86	1.87[0.26–13.44]	0.53
[weeks]	24	13	1	8	12	92	Ref
Weight gain (kg)	>14	34	3	9	31	91	0.61[0.19–1.94]	0.40
from baseline to	10.01–14.0	64	7	11	57	89	0.76[0.35–1.65]	0.48
end of treatment	6.01–10.0	202	28	14	174	86	0.96[0.62–1.49]	0.85
	≤ 2	187	31	17	156	83	1.15[0.75–1.75]	0.53
	No	141	21	15	120	85	1.02[0.63–1.68]	0.90
	2.01 to 6.0	470	68	14	402	86	Ref
Missed doses in	>12	11	4	36	7	64	2.72[1.00–7.36]	0.05	1.22[0.73–2.05]	0.44
Intensive phase	7 to 12	20	4	20	16	80	1.50[0.55–4.05]	0.43	0.99[0.59–1.67]	0.99
of treatment	1 to 6	121	23	19	98	81	1.42[0.91–2.22]	0.12	0.77[0.26–2.27]	0.64
	No	950	127	13	823	87	Ref		Ref

RR—Relative risk, ARR—Adjusted relative risk, CI: Confidence Interval